PMID- 32316225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 16
TI  - Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and 
      Proliferation of Pituitary Neuroendocrine Tumours.
LID - 10.3390/diagnostics10040227 [doi]
LID - 227
AB  - miR-17-5p and E2F1 have been described as deregulated in cancer, but they have 
      scarcely been studied in pituitary neuroendocrine tumours (PitNETs). This study 
      evaluates the relationship of E2F1 and miR-17-5p with the invasiveness and 
      proliferation of PitNETs. In this cross-sectional descriptive study, we evaluated 
      the expression of E2F1, MYC, and miR-17-5p by quantitative real time PCR analysis 
      in 60 PitNETs: 29 gonadotroph (GT), 15 functioning somatotroph (ST), and 16 
      corticotroph (CT) tumours, of which 8 were silent (sCT). The clinical data were 
      collected from the Spanish Molecular Register of Pituitary Adenomas (REMAH) 
      database. We defined invasiveness according to the Knosp classification and 
      proliferation according to a molecular expression of Ki-67 >/= 2.59. E2F1 was more 
      expressed in invasive than in non-invasive tumours in the whole series (p = 
      0.004) and in STs (p = 0.01). In addition, it was overexpressed in the silent 
      subtypes (GTs and sCTs; all macroadenomas) and normoexpressed in the functioning 
      ones (fCTs and STs; some microadenomas). miR-17-5p was more expressed in 
      proliferative than in non-proliferative tumours (p = 0.041) in the whole series 
      but not by subtypes. Conclusions: Our study suggests that in PitNETs, E2F1 could 
      be a good biomarker of invasiveness, and miR-17-5p of proliferation, helping the 
      clinical management of these tumours.
FAU - Garcia-Martinez, Araceli
AU  - Garcia-Martinez A
AUID- ORCID: 0000-0002-1052-1315
AD  - Research Laboratory, Hospital General Universitario de Alicante-Institute for 
      Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain.
FAU - Lopez-Munoz, Beatriz
AU  - Lopez-Munoz B
AD  - Department of Endocrinology & Nutrition, Hospital General Universitario de 
      Alicante-ISABIAL, 03010 Alicante, Spain.
FAU - Fajardo, Carmen
AU  - Fajardo C
AD  - Department of Endocrinology and Nutrition, Hospital La Ribera, Alzira, 46600 
      Valencia, Spain.
FAU - Camara, Rosa
AU  - Camara R
AD  - Department of Endocrinology & Nutrition, Hospital Universitario y Politecnico La 
      Fe, 46026 Valencia, Spain.
FAU - Lamas, Cristina
AU  - Lamas C
AUID- ORCID: 0000-0003-4622-9508
AD  - Department of Endocrinology & Nutrition, Hospital General Universitario de 
      Albacete, 02006 Albacete, Spain.
FAU - Silva-Ortega, Sandra
AU  - Silva-Ortega S
AD  - Department of Pathology, Hospital General Universitario de Alicante -ISABIAL, 
      03010 Alicante, Spain.
FAU - Aranda, Ignacio
AU  - Aranda I
AD  - Department of Pathology, Hospital General Universitario de Alicante -ISABIAL, 
      03010 Alicante, Spain.
FAU - Pico, Antonio
AU  - Pico A
AD  - Department of Endocrinology & Nutrition, Hospital General Universitario de 
      Alicante, Miguel Hernandez University, 03010 Alicante, Spain.
LA  - eng
GR  - WS1568384/Pfizer/
PT  - Journal Article
DEP - 20200416
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7235816
OTO - NOTNLM
OT  - E2F1
OT  - miR-17~92
OT  - microRNAs
OT  - pituitary neuroendocrine tumours
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
PMCR- 2020/04/16
CRDT- 2020/04/23 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/04/12 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
PHST- 2020/04/16 00:00 [pmc-release]
AID - diagnostics10040227 [pii]
AID - diagnostics-10-00227 [pii]
AID - 10.3390/diagnostics10040227 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 Apr 16;10(4):227. doi: 10.3390/diagnostics10040227.